AstraZeneca to invest over US$1bil in Massachusetts, boost workforce
NEW YORK: AstraZeneca said on Monday it would spend more than US$1 billion in Massachusetts as part of its broader US$50 billion US investment plan, a move expected to expand its workforce in the state by more than 50 per cent in the coming years.
AstraZeneca plans to invest over US$1 billion in Massachusetts as part of its larger US$50 billion US investment strategy. This significant move is expected to grow the company's workforce in the state by over 50% in the years to come. In addition to opening a new research and development center in Cambridge, Massachusetts, AstraZeneca is expanding its presence in the United States.
The 570,000-square-foot, 18-story facility in Kendall Square will primarily focus on developing treatments for cancer, chronic, and rare diseases, as well as cell therapies. With nearly 2,000 researchers and scientists working in the center, it will complement AstraZeneca's nearby genomic medicine site. The new facility features 10 floors of laboratories, equipped with cutting-edge technology such as robotics, automation, and artificial intelligence.
AstraZeneca already operates 24 research, manufacturing, commercial, and corporate sites across the US, employing more than 25,000 people in the country.
Written by urgent.news from New Straits Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.